Home>>Signaling Pathways>> Cardiovascular>> Vasoconstriction>>Endothelin-3 (human, rat) (trifluoroacetate salt)

Endothelin-3 (human, rat) (trifluoroacetate salt) (Synonyms: ET-3)

Catalog No.GC43608

Endothelin-3 is a peptide vasoconstricter and a ligand of the endothelin (ET) receptors ETA and ETB (Kbs = 1.05 and 1.49, respectively).

Products are for research use only. Not for human use. We do not sell to patients.

Endothelin-3 (human, rat) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
100μg
$302.00
In stock
250μg
$528.00
In stock
500μg
$679.00
In stock
1mg
$754.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Endothelin-3 is a peptide vasoconstricter and a ligand of the endothelin (ET) receptors ETA and ETB (Kbs = 1.05 and 1.49, respectively). It induces β-arrestin recruitment in CHO-K1 cells expressing human ETA and ETB (pD2s = 7.31 and 9.44, respectively). Endothelin-3 increases blood pressure in spontaneously hypertensive and normotensive rats when administered at doses of 310 and 955 pmol/kg, respectively. It also stimulates migration and adhesion of enteric neural crest cells (ENCCs) to the embryonic gut in mice via interaction with ETB. Mutations in the endothelin-3 gene, Edn3, induce distal aganglionosis caused by failed colonization of ENCCs in the hindgut and lack of ENCC migration to the ileo-caecal junction in mice.

Reviews

Review for Endothelin-3 (human, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Endothelin-3 (human, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.